Anika Therapeutics raised its full-year 2026 revenue and adjusted EBITDA guidance following a second quarter in which total revenue grew 16% to $32.6 million and gross margin expanded to 65%. Commercial channel revenue reached a record $13.9 million, up 17% year over year, while international revenue also hit a record $12.6 million, a 22% increase driven by market share gains in osteoarthritis pain management and higher contributions from regenerative solutions. OEM channel revenue rose 14% to $18.7 million, supported by favorable order timing and Monovisc unit volumes exceeding projections. Adjusted EBITDA was $7.1 million, the highest since 2020, and net income was $3.3 million. The company now expects total revenue growth of 5% to 10%, up from a prior range of 1% to 9%, and adjusted EBITDA margin of 13% to 17%, up from 5% to 10%. For 2027, Anika introduced a new policy to exclude revenue from unapproved products such as Hyalofast, resulting in a forecast of 0% to 5% total company revenue growth.
Anika Therapeutics IncRaises full-year guidance and reports record revenue and margin expansion.
Commercial Metals Company